SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humans (English)
- New search for: Lazaar, Aili L.
- New search for: Sweeney, Lisa E.
- New search for: MacDonald, Alexander J.
- New search for: Alexis, Neil E.
- New search for: Chen, Chao
- New search for: Tal‐Singer, Ruth
- New search for: Lazaar, Aili L.
- New search for: Sweeney, Lisa E.
- New search for: MacDonald, Alexander J.
- New search for: Alexis, Neil E.
- New search for: Chen, Chao
- New search for: Tal‐Singer, Ruth
In:
British Journal of Clinical Pharmacology
;
72
, 2
;
282-293
;
2011
- Article (Journal) / Electronic Resource
-
Title:SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humans
-
Contributors:Lazaar, Aili L. ( author ) / Sweeney, Lisa E. ( author ) / MacDonald, Alexander J. ( author ) / Alexis, Neil E. ( author ) / Chen, Chao ( author ) / Tal‐Singer, Ruth ( author )
-
Published in:British Journal of Clinical Pharmacology ; 72, 2 ; 282-293
-
Publisher:
- New search for: Blackwell Publishing Ltd
-
Publication date:2011-08-01
-
Size:12 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Keywords:
-
Source:
Table of contents – Volume 72, Issue 2
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 183
-
Clinical pharmacology of functional disorders of the urogenital systemMichel, Martin C. et al. | 2011
- 186
-
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunctionAndersson, Karl‐Erik / Campeau, Lysanne / Olshansky, Brian et al. | 2011
- 197
-
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunctionÜckert, Stefan / Oelke, Matthias et al. | 2011
- 205
-
α1‐Adrenoceptors and muscarinic receptors in voiding function – binding characteristics of therapeutic agents in relation to the pharmacokineticsYamada, Shizuo / Ito, Yoshihiko / Tsukada, Hideo et al. | 2011
- 218
-
Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?Korstanje, Cees / Krauwinkel, Walter / van Doesum‐Wolters, Francisca L. C. et al. | 2011
- 226
-
Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizersMalhotra, Bimal / Darsey, Edress / Crownover, Penelope / Fang, Juanzhi / Glue, Paul et al. | 2011
- 235
-
A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladderCallegari, Ernesto / Malhotra, Bimal / Bungay, Peter J. / Webster, Rob / Fenner, Katherine S. / Kempshall, Sarah / LaPerle, Jennifer L. / Michel, Martin C. / Kay, Gary G. et al. | 2011
- 247
-
Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosinTroost, Joachim / Tatami, Shinji / Tsuda, Yasuhiro / Mattheus, Michaela / Mehlburger, Ludwig / Wein, Martina / Michel, Martin C. et al. | 2011
- 257
-
Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteersMalhotra, Bimal / Alvey, Christine / Gong, Jason / Li, Xiaoxi / Duczynski, Gregory / Gandelman, Kuan et al. | 2011
- 263
-
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjectsMalhotra, Bimal / Dickins, Maurice / Alvey, Christine / Jumadilova, Zhanna / Li, Xiaoxi / Duczynski, Gregory / Gandelman, Kuan et al. | 2011
- 270
-
Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human studyXu, Zhenhua / Bouman‐Thio, Esther / Comisar, Craig / Frederick, Bart / Van Hartingsveldt, Bart / Marini, Joseph C. / Davis, Hugh M. / Zhou, Honghui et al. | 2011
- 282
-
SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humansLazaar, Aili L. / Sweeney, Lisa E. / MacDonald, Alexander J. / Alexis, Neil E. / Chen, Chao / Tal‐Singer, Ruth et al. | 2011
- 294
-
Population pharmacokinetic analysis of sorafenib in patients with solid tumoursJain, Lokesh / Woo, Sukyung / Gardner, Erin R. / Dahut, William L. / Kohn, Elise C. / Kummar, Shivaani / Mould, Diane R. / Giaccone, Giuseppe / Yarchoan, Robert / Venitz, Jürgen et al. | 2011
- 306
-
Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgELowe, Philip J. / Renard, Didier et al. | 2011
- 321
-
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteersAllred, Alicia J. / Bowen, Carolyn J. / Park, Jung Wook / Peng, Bin / Williams, Daphne D. / Wire, Mary Beth / Lee, Edmund et al. | 2011
- 330
-
Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997–2007Zamparutti, Giuliano / Schifano, Fabrizio / Corkery, John M. / Oyefeso, Adenekan / Ghodse, A. Hamid et al. | 2011
- 338
-
Pilot of a National Inpatient Medication Chart in Australia: improving prescribing safety and enabling prescribing trainingCoombes, Ian D. / Reid, Carol / McDougall, David / Stowasser, Danielle / Duiguid, Margaret / Mitchell, Charles et al. | 2011
- 350
-
Important details to be clarified about the effect of rectal ozone on the portal vein oxygenationBocci, Velio / Zanardi, Iacopo / Travagli, Valter et al. | 2011
- 353
-
Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterolDaley‐Yates, Peter T. / Parkins, David A. et al. | 2011
- 355
-
Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone and salmeterol: a replyLipworth, Brian J. / Clearie, Karine L. et al. | 2011
- 357
-
Translation Section| 2011
- 365
-
Erratum| 2011